Headlines about Innoviva (NASDAQ:INVA) have trended somewhat positive recently, Accern Sentiment reports. The research group scores the sentiment of news coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Innoviva earned a daily sentiment score of 0.07 on Accern’s scale. Accern also assigned press coverage about the biotechnology company an impact score of 44.578177060505 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
These are some of the media headlines that may have effected Accern’s scoring:
A number of research firms have recently weighed in on INVA. ValuEngine upgraded shares of Innoviva from a “hold” rating to a “buy” rating in a report on Monday, October 2nd. Stifel Nicolaus reiterated a “neutral” rating on shares of Innoviva in a report on Friday, September 15th. BidaskClub upgraded shares of Innoviva from a “hold” rating to a “buy” rating in a report on Thursday, December 21st. Zacks Investment Research upgraded shares of Innoviva from a “hold” rating to a “buy” rating and set a $16.00 target price for the company in a report on Wednesday, October 25th. Finally, Robert W. Baird restated a “hold” rating and issued a $13.00 price objective on shares of Innoviva in a report on Tuesday, October 24th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and three have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average price target of $13.50.
Shares of Innoviva (NASDAQ INVA) traded up $0.01 on Friday, reaching $14.54. 944,304 shares of the company’s stock traded hands, compared to its average volume of 643,202. The company has a quick ratio of 6.71, a current ratio of 6.71 and a debt-to-equity ratio of -2.59. Innoviva has a twelve month low of $10.30 and a twelve month high of $14.87. The stock has a market capitalization of $1,569.46, a price-to-earnings ratio of 16.71 and a beta of 2.52.
Innoviva (NASDAQ:INVA) last issued its quarterly earnings data on Wednesday, October 25th. The biotechnology company reported $0.21 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.34 by ($0.13). Innoviva had a negative return on equity of 33.55% and a net margin of 52.91%. The company had revenue of $48.64 million during the quarter, compared to analysts’ expectations of $57.18 million. During the same quarter last year, the business earned $0.13 earnings per share. The business’s quarterly revenue was up 46.0% on a year-over-year basis. analysts anticipate that Innoviva will post 1.08 earnings per share for the current fiscal year.
In other Innoviva news, insider Michael W. Aguiar sold 12,022 shares of the firm’s stock in a transaction that occurred on Monday, December 4th. The shares were sold at an average price of $13.13, for a total transaction of $157,848.86. Following the completion of the transaction, the insider now owns 980,907 shares of the company’s stock, valued at $12,879,308.91. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP George B. Abercrombie sold 5,215 shares of the firm’s stock in a transaction that occurred on Tuesday, November 21st. The shares were sold at an average price of $13.26, for a total transaction of $69,150.90. Following the transaction, the vice president now directly owns 263,866 shares of the company’s stock, valued at approximately $3,498,863.16. The disclosure for this sale can be found here. Insiders sold 32,522 shares of company stock valued at $429,985 over the last 90 days. 1.60% of the stock is currently owned by company insiders.
WARNING: “Innoviva (INVA) Receiving Somewhat Positive Press Coverage, Analysis Finds” was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece of content on another site, it was copied illegally and republished in violation of US & international trademark & copyright law. The correct version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/01/13/somewhat-positive-media-coverage-somewhat-unlikely-to-impact-innoviva-inva-share-price-2.html.
Innoviva Company Profile
Innoviva, Inc, formerly Theravance, Inc, is engaged in the development, commercialization and financial management of bio-pharmaceuticals. It focuses on the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate (FF)/vilanterol (VI)) and ANORO ELLIPTA (umeclidinium bromide/vilanterol (UMEC/VI)).
Receive News & Ratings for Innoviva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innoviva and related companies with MarketBeat.com's FREE daily email newsletter.